venBio entities tied to Corey Goodman add ALX Oncology (ALXO) with 3,184,713-share buy

Rhea-AI Filing Summary

ALX Oncology director and 10% owner Corey S. Goodman, through entities associated with venBio, reported a large indirect purchase of the company’s common stock. On February 2, 2026, venBio Global Strategic Fund II, L.P. acquired 3,184,713 ALX Oncology shares at $1.57 per share, bringing its indirectly reported holdings to 8,453,038 shares. Additional indirect holdings reported for entities linked to Goodman include 3,969,789 shares held by venBio Global Strategic Fund, L.P., 461,811 shares held by venBio SPV, LLC, 113,287 shares held by the Goodman Barinaga Trust, and 54,083 shares held by Emaldi Corporation. Goodman serves in oversight roles at these entities and disclaims beneficial ownership of the securities, except to the extent of his indirect pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOODMAN COREY S

(Last) (First) (Middle)

C/O VENBIO PARTNERS, LLC

1700 OWENS STREET, SUITE 595

(Street)

SAN FRANCISCO CA 94010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		P		3,184,713	A	$1.57	8,453,038	I	See footnote(1)
Common Stock								3,969,789	I	See footnote(2)
Common Stock								461,811	I	See footnote(3)
Common Stock								113,287	I	See footnote(4)
Common Stock								54,083	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

2. The shares are held of record by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. The reporting person, a director of venBio Global Strategic GP, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

3. The shares are held of record by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. The reporting person, a managing director of venBio SPV, LLC, disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

4. The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee.

5. The shares are held of record by Emaldi Corporation for which the reporting person serves as a director. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

	/s/ Shelly Pinto, by power of attorney	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALX Oncology (ALXO) report on February 2, 2026?

ALX Oncology reported an indirect purchase of 3,184,713 common shares at $1.57 each on February 2, 2026 by venBio Global Strategic Fund II, L.P., an entity associated with director and 10% owner Corey S. Goodman, as disclosed in a Form 4 filing.

Who is the reporting person in the February 2026 ALX Oncology (ALXO) Form 4?

The reporting person is Corey S. Goodman, identified as a director and 10% owner of ALX Oncology Holdings Inc. The Form 4 shows that the reported ALXO shares are held indirectly through various entities, and Goodman disclaims beneficial ownership except for his indirect pecuniary interest.

Which entity bought 3,184,713 ALX Oncology (ALXO) shares and at what price?

venBio Global Strategic Fund II, L.P. bought 3,184,713 ALX Oncology common shares at $1.57 per share. This holding is reported indirectly for director and 10% owner Corey S. Goodman, who serves as a director of the fund’s general partner and disclaims full beneficial ownership.

How many ALX Oncology (ALXO) shares did venBio Global Strategic Fund II, L.P. hold after the transaction?

After the February 2, 2026 transaction, venBio Global Strategic Fund II, L.P. was reported as indirectly holding 8,453,038 ALX Oncology common shares. These shares are attributed to director Corey S. Goodman only to the extent of his indirect pecuniary interest, according to the Form 4 footnotes.

What other ALX Oncology (ALXO) indirect holdings are reported for entities linked to Corey S. Goodman?

The filing reports 3,969,789 ALXO shares held by venBio Global Strategic Fund, L.P., 461,811 by venBio SPV, LLC, 113,287 by the Goodman Barinaga Trust, and 54,083 by Emaldi Corporation. Goodman has roles with these entities but disclaims beneficial ownership beyond any indirect pecuniary interest.

Does Corey S. Goodman claim full beneficial ownership of the reported ALX Oncology (ALXO) shares?

No. For shares held by venBio funds, venBio SPV, LLC, and Emaldi Corporation, Corey S. Goodman expressly disclaims beneficial ownership except to the extent of his indirect pecuniary interest. He also reports shares held by the Goodman Barinaga Trust, where he serves as trustee.